Form 4: Stoke Therapeutics CMO Executes Stock Sale

Chief Medical Officer Barry Ticho sold 1,795 shares of Stoke Therapeutics common stock via a pre-arranged 10b5-1 plan.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold 1,795 shares of common stock.
• The transaction occurred on June 1, 2026, at a price of $30.58 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 34,826 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard administrative practice.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• General market volatility affecting biotechnology sector valuations.
• Reliance on Rule 10b5-1 plans does not eliminate the risk of negative market perception regarding insider selling.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common practice in the biotechnology sector and typically does not signal a change in corporate strategy or internal sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the officer's total holdings.

Key Dates

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Biotechnology, Chief Medical Officer